#MRCWIMM is proud to contribute to research that improves health and wellbeing worldwide. Happy #WorldHealthDay!
@medsci.ox.ac.uk @ox.ac.uk @rdm.ox.ac.uk #AcademicSky 🧪

Image showing a PICO summary for: Use of #albumin in patients with hepatic encephalopathy: A #systematicreview and #metaanalysis of randomized controlled studies with trial sequential analysis by Coan et al. featured in the Transfusion Evidence Alert - March 2026

New from the #Transfusion Evidence Alert:

Use of #albumin in patients with hepatic encephalopathy: A #systematicreview and #metaanalysis of randomized controlled studies with trial sequential analysis
by Coan et al.
Link in the comments
#MedSky

Image showing a PICO summary for: Comparative efficacy of prehospital resuscitation strategies on mortality for patients with major trauma: a network meta-analysis by Hsu et al. featured in the Transfusion Evidence Alert - March 2026

From the #Transfusion Evidence Alert:

Comparative efficacy of prehospital resuscitation strategies on mortality for patients with major trauma: a network #meta-analysis
by Hsu et al.
🔗 Link in the comments
#MedSky

Who is the best allogeneic hematopoietic stem cell transplant donor for severe aplastic anemia? Data from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG) Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for severe aplastic anemia (SAA), with donor sources including matched sibling donors (MSDs), haploidentical donors (HIDs), and unrelated donors (URDs). However, the optimal criteria for donor selection remain undefined. We performed a multicenter retrospective study of 795 consecutive SAA patients who underwent allo-HSCT between 2012 and 2020 across 11 transplant centers in China. The overall survival (OS), failure-free survival (FFS), and GVHD-free/FFS (GFFS) rates were 85.2%, 83.6%, and 76.1%, respectively. Donor-related variables including relationship, age, sex match, blood type, and HLA mismatches were evaluated. Multivariable Cox regression identified donor age ≥50 years as an independent risk factor for inferior GFFS (HR = 2.13), OS (HR = 2.09), and FFS (HR = 2.18) (all P < 0.001). To directly compare the prognostic weight of donor age versus HLA compatibility, we stratified patients into four subgroups according to donor type (HID vs. MSD) and donor age (<50 vs. ≥50 years). Kaplan-Meier analysis with log-rank testing revealed that recipients of haploidentical grafts from younger donors achieved superior OS and FFS compared with those transplanted from older HLA-matched sibling donors. These findings demonstrate that donor age has a greater influence on transplant outcomes than HLA matching. With continuous improvements in haploidentical transplantation techniques, selecting younger haploidentical donors may represent a more favorable strategy than choosing older matched sibling donors.

🔗 #StemCellEvidence link to:
Who is the best allogeneic hematopoietic stem cell transplant donor for severe aplastic anemia? Data from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG)
by Xu et al.
www.stemcellevidence.com/alerts/artic...
#MedSky

Image showing a PICO summary for: Who is the best allogeneic hematopoietic stem cell transplant donor for severe aplastic anemia? Data from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG) by Xu et al. featured in the Stem Cell Evidence Alert - March 2026

New from the #StemCellEvidence Alert:

Who is the best allogeneic hematopoietic stem cell transplant donor for severe aplastic anemia? Data from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG)
by Xu et al.
🔗 Link in the comments
#MedSky

Science shows what is possible. From breakthrough medicines and clean air to life-saving vaccines and new discoveries — science works for all of us, every day.

This #WorldHealthDay, let's come together and #StandWithScience. 💙

GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial Acute myeloid leukemia (AML) is the most common indication for allogeneic hematopoietic cell transplantation (alloHCT), yet graft-versus-host disease (GVHD) remains a major post-transplant complication. Conditioning regimens, particularly reduced-intensity approaches, are critical in optimizing outcomes. This subgroup analysis of the phase 3 MC-FludT.14/L trial compared treosulfan-fludarabine with reduced-intensity busulfan-fludarabine in 352 AML patients (aged 31-70) undergoing alloHCT. The primary endpoint was 24-month event-free survival (EFS); secondary endpoints included overall survival (OS), GVHD incidence, relapse/progression, and non-relapse mortality (NRM). Treosulfan compared to busulfan demonstrated superiority: 24-month EFS was 65% vs. 53% (p = 0.01), and OS was 73% vs. 65%. EFS benefits were consistent across AML risk categories and notably higher in patients with hematopoietic cell transplantation comorbidity index >2 (62% vs. 42%, p = 0.02). Treosulfan also showed lower NRM and relapse rates. GVHD outcomes favored treosulfan, with a significantly lower incidence of extensive chronic GVHD at 24 months (15.1% vs. 28.1%, p = 0.01). GVHD-free and relapse-free survival was also improved (53% vs. 40%, p = 0.02). The safety profile was more favorable with treosulfan. These findings support treosulfan-fludarabine as a more effective and safer conditioning regimen than busulfan-fludarabine for AML patients undergoing alloHCT, particularly those at higher risk.

🔗 #StemCellEvidence link to:
GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial
by Stölzel et al.
www.stemcellevidence.com/alerts/artic...
#MedSky

Image showing a PICO summary for: GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial by Stölzel et al. featured in the Stem Cell Evidence Alert - March 2026

From the #StemCellEvidence Alert:

GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial
by Stölzel et al.
🔗 Link in the comments
#MedSky

Phase I/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease Chronic Graft versus Host Disease (cGVHD) remains a major hurdle to the success of hematopoietic stem cell transplantation (HSCT), directly impacting patient morbidity and mortality. Impaired Treg recovery in patients with cGVHD has led to clinical studies aiming to increase peripheral Treg numbers. We performed Phase I dose escalation clinical trials, testing the feasibility and safety of using freshly isolated donor-derived Treg infusions in steroid-refractory/dependent cGVHD. The Phase I was extended to a preliminary Phase II trial, resulting in a total of 33 treated patients. We report that Treg purification from donor leukapheresis using CliniMACS were feasible and that Treg infusions were safe. Importantly, Treg infusions resulted in improved symptoms, particularly at higher Treg doses. Global responses were observed in 71% of patients, and 52% of patients had at least a 2-point improvement in the cGVHD severity scale. Furthermore, improvement in cGVHD symptoms resulted in reductions in corticosteroids, ruxolitinib and mycophenolate (MMF) in 58%, 83% and 33% of patients, respectively, while calcineurin inhibitors were discontinued in 75% of patients. Exploratory analyses revealed the detection of infused Treg clonotypes up to 12 months post-infusion and suggest increased Treg numbers in circulation. We observed increases in serum levels of IL-7, IFN-g, and decreases in sCD13 and ST2 over time, which were not statistically significant following adjustment for multiple comparisons. Although these studies were not powered to assess efficacy, they suggest potential therapeutic benefits of donor-derived Treg in cGVHD treatment and highlight the need for larger Phase II clinical trials. NCT02385019 NCT03683498 (clinicaltrials.gov).

🔗 #StemCell Evidence link to:
Phase I/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease
by Soares et al.
www.stemcellevidence.com/alerts/artic...
#MedSky

Image showing a PICO summary for: Phase I/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease by Soares et al. featured in the Stem Cell Evidence Alert - March 2026

New from the #StemCellEvidence Alert:

Phase I/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease
by Soares et al.
🔗 Link in the comments
#MedSky

Image showing a PICO summary for: Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial by Broderick et al. featured in the Transfusion Evidence Alert - March 2026

New from #Transfusion Evidence Library:

Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
by Broderick et al.
🔗 Link in the comments

Longitudinal Study of Late Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: A Long-Term Follow-up Study from the Chronic Graft-Versus-Host Disease Consortium Late acute and chronic graft-versus-host disease (GVHD) contribute to morbidity and death after allogeneic hematopoietic cell transplantation (HCT). A prior national Chronic GVHD Consortium longitudinal study enrolled patients pre- or early post-HCT and identified the incidence of late acute GVHD, chronic GVHD, and chronic GVHD subtypes of bronchiolitis obliterans syndrome (BOS) and cutaneous sclerosis. We now report 10-yr follow-up from that study in a long-term follow-up analysis (N = 911 subjects). Late acute GVHD occurred in 11% at a median of 5.5 mo. Chronic GVHD in total occurred in 54% with median onset of 7.4 mo. BOS (4% of subjects, median onset 12.6 mo) and cutaneous sclerosis (10% of subjects, median onset of 17.2 mo) were less frequent and had later-onset. The long-term analysis demonstrated additional GVHD events occurring beyond 1 to 2 yr post-HCT. Inter-conversion between GVHD types was common, and notably included new development of BOS and cutaneous sclerosis after initial chronic GVHD presentation without these manifestations. GVHD-free, relapse-free survival (GVHD-DFS, survival without relapse or development of late acute or chronic GVHD) was 22% at 2 yr, 18% at 5 yr, and 15% at 10 yr post-HCT. Non-relapse mortality continued to increase beyond 2 yr, with 10-yr estimates up to 35% (late acute), 31% (chronic GVHD), 62% (BOS), and 36% (cutaneous sclerosis). Durable complete discontinuation of immune suppression was uncommon for all GVHD types. These data suggest that extended surveillance for late acute and chronic GVHD is needed post-HCT due to late occurrences, and that associated mortality is high through 10 yr post-GVHD onset.

🔗 #StemCellEvidence link:
Longitudinal Study of Late Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: A Long-Term Follow-up Study from the Chronic Graft-Versus-Host Disease Consortium
by Pidala et al.
www.stemcellevidence.com/alerts/artic...
#MedSky

Image showing a PICO summary for: Longitudinal Study of Late Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: A Long-Term Follow-up Study from the Chronic Graft-Versus-Host Disease Consortium by Pidala et al. featured in the Stem Cell Evidence Alert - March 2026

From the #StemCellEvidence Alert:

Longitudinal Study of Late Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: A Long-Term Follow-up Study from the Chronic Graft-Versus-Host Disease Consortium
by Pidala et al.
Link in the comments
#MedSky

Image showing a PICO summary for: N-acetylcysteine reduces incidence and duration of linezolid-associated thrombocytopenia in critically ill patients: A randomized controlled trial by Abdeltawab et al. featured in the Transfusion Evidence Alert - March 2026

From the #Transfusion Evidence Alert:

N-acetylcysteine reduces incidence and duration of linezolid-associated thrombocytopenia in critically ill patients: A randomized controlled trial
by Abdeltawab et al.

🔗link in the comments
#MedSky

The role of HLA transcription in unrelated hematopoietic cell transplantation Expression levels of human leukocyte antigen (HLA) are associated with susceptibility to various diseases and outcomes after allogeneic hematopoietic cell transplantation (allo-HCT). However, there has been no comprehensive analysis of the effect of the expression levels of the HLA-A, -B, -C, and -DRB1 alleles in unrelated (UR)-HCT. Using the Capture RNA-Seq method, we analyzed the gene expression of HLA alleles in 443 healthy donors and determined the allele-specific transcription levels (AST levels). We assigned median (M)-AST levels to HLA typing data of patients who received a transplant from HLA-A, -B, -C, and -DRB1-matched unrelated donors using transplant registry data. All 6,084 patients were divided into low, middle, and high tertile groups according to the distribution of the sum of the two alleles of the M-AST level for each HLA locus and the sum of the eight alleles of the M-AST level for all four loci. The risk of grade II-IV acute graft-versus-host disease (GVHD) was significantly higher in the middle group (hazard ratio, 1.11; P = 0.044) and high group (hazard ratio, 1.20; P < 0.001) than in the low group for the sum of the HLA-A, -B, -C, and -DRB1 loci. Similar results were observed at the HLA-A, -B, -C, and -DRB1 loci. Higher transcription levels were also associated with a lower risk of relapse at the HLA-B, -C, and -DRB1 loci. Our data suggest that a high transcription level of patient and/or donor HLA may evoke strong alloimmune responses and affect UR-HCT outcomes.

#StemCellEvidence link to:
The role of HLA transcription in unrelated hematopoietic cell transplantation
by Morishima et al.
www.stemcellevidence.com/alerts/artic...
#MedSky

Image showing a PICO summary for: The role of HLA transcription in unrelated hematopoietic cell transplantation by Morishima et al. featured in the Stem Cell Evidence Alert - March 2026

New from the #StemCellEvidence Alert:

The role of HLA transcription in unrelated hematopoietic cell transplantation
by Morishima et al.
🔗Link in the comments
#MedSky

Bone marrow transplantation for sickle cell disease using post-transplantation cyclophosphamide and 400 cGy TBI Reduced intensity conditioning (RIC), haploidentical donors, and post-transplantation cyclophosphamide (PTCy) have overcome many barriers associated with bone marrow transplantation (BMT) for sickle cell disease (SCD). However, initial approaches had high graft failure rates. Our preliminary data suggested increasing the total body irradiation (TBI) dose from 200 to 400 cGy could improve engraftment. This study included SCD patients aged 2-70 undergoing BMT from November 2014 - January 2025. The regimen included anti-thymocyte globulin, fludarabine, cyclophosphamide, and single fraction 400 cGy TBI. Graft-vs-host disease (GVHD) prophylaxis included PTCy, mycophenolate mofetil, and sirolimus. Outcomes measured were disease-free survival (DFS), graft failure, overall survival (OS), and GVHD incidence. Forty-three patients (median age 23) were transplanted. Thirty-four (79%) had >2 indications for BMT and all had >2 SCD comorbidities. Five-year OS probability was 95.5% (CI 0.87 - 1.0) at a median follow-up of 2.43 years. DFS probability at 2 years was 94.5% (CI 0.87 - 1.0) with only 2 (5%) graft failures. Two patients died late (2.5 and 6 years) after BMT. The cumulative incidence of grades 3-4 acute GVHD was 2.4% (CI 0 - 0.07) and moderate-severe chronic GVHD was 7.3% (CI 0 - 0.15). Median time to discontinuation of immunosuppression was 354 days. Of the 27 female patients, 12 had return of menses and/or normalized gonadal function. RIC haploidentical BMT with 400 cGy maintained a low toxicity profile, provides high rates of durable engraftment, and may preserve fertility. This regimen expands the availability of curative therapy for severe SCD. NCT00489281.

🔗 #StemCellEvidence link to:
Bone marrow transplantation for sickle cell disease using post-transplantation cyclophosphamide and 400 cGy TBI
by Goldenberg et al.
www.stemcellevidence.com/alerts/artic...
#MedSky

Image showing a PICO summary for: Bone marrow transplantation for sickle cell disease using post-transplantation cyclophosphamide and 400 cGy TBI by Goldenberg et al. featured in the Stem Cell Evidence Alert - March 2026

New from the #StemCellEvidence Alert:

Bone marrow transplantation for sickle cell disease using post-transplantation cyclophosphamide and 400 cGy TBI
by Goldenberg et al.
🔗Link in the comments
#MedSky

Image showing a PICO summary for: Preventive interventions for vasovagal reactions in whole blood donors: a cluster-randomised, stepped-wedge, crossover trial of 73 sites involving 1·4 million donors in England by Kaptoge et al. featured in the Transfusion Evidence Alert - March 2026

New from the #Transfusion Evidence Alert:

Preventive interventions for vasovagal reactions in whole blood donors: a cluster-randomised, stepped-wedge, crossover trial of 73 sites involving 1·4 million donors in England
by Kaptoge et al.

🔗Link in the comments
#MedSky

The BIOPREVENT machine-learning algorithm predicts chronic graft-versus-host disease and mortality risk using posttransplant biomarkers BACKGROUNDChronic graft-versus-host disease (cGVHD) is a major contributor to nonrelapse mortality (NRM) following hematopoietic cell transplantation (HCT). Whether machine-learning (ML) models with biomarkers improve the accuracy for predicting future cGVHD/NRM is not established.METHODSWe developed BIOPREVENT (BIOmarkers PREVENTion), a ML algorithm using data from 1,310 HCT recipients, incorporating 7 plasma proteins measured at Day 90/100 post-HCT and 9 clinical variables. Patients were divided into training and validation datasets. ML models - including CoxXGBoost, Group SCAD, Adaptive Group Lasso, Random Survival Forests, and Bayesian Additive Regression Trees (BART) - were used to estimate time-varying Area Under the ROC Curve (AUCt) at Days 180, 270, 360, and 540. Deep learning models were also evaluated.RESULTSML models with biomarkers outperformed clinical-only models for predicting cGVHD, with BART and CoxXGBoost achieving AUCt greater than 0.65 at 1 year. For NRM, models with biomarkers achieved AUCt ranging from 0.75-0.91. Deep learning did not outperform other ML approaches. BART consistently demonstrated high predictive accuracy and was selected for the final BIOPREVENT model. Calibration curves aligned with observed values. Variable importance analysis identified MMP3 and CXCL9 as key for cGVHD prediction and IL1RL1 and sCD163 for NRM. Cumulative incidences of cGVHD and NRM differed significantly based on BIOPREVENT-defined cutpoints.CONCLUSIONBIOPREVENT accurately predicts individual risk of future cGVHD and NRM using biomarkers at 3 months post-HCT. A publicly available R Shiny web application supports its clinical use. Further studies are needed to explore its role in guiding preemptive therapy.TRIAL REGISTRATIONBMTCTN 0201, BMTCTN 1202, and NCT02194439.FUNDINGR01CA264921, U10HL069294, U24HL138660, R01HD074587, and P01HL158505.

#StemCellEvidence link to:
The BIOPREVENT machine-learning algorithm predicts chronic graft-versus-host disease and mortality risk using posttransplant biomarkers
by Martens et al.
www.stemcellevidence.com/alerts/artic...
#MedSky

Image showing a PICO summary for: The BIOPREVENT machine-learning algorithm predicts chronic graft-versus-host disease and mortality risk using posttransplant biomarkers by Martens et al. featured in the Stem Cell Evidence Alert - March 2026

From the #StemCellEvidence Alert:

The BIOPREVENT machine-learning algorithm predicts chronic graft-versus-host disease and mortality risk using posttransplant biomarkers
by Martens et al.

🔗Link in the comments

Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation Risk stratification in myelodysplastic syndromes (MDS) is essential for clinical decision-making, yet the optimal approach to estimate risk for patients undergoing allogeneic stem cell transplantation (alloHSCT) remains uncertain. Whether dynamic changes in risk between diagnosis and post-hypomethylating agent (HMA) therapy improve prognostic accuracy beyond baseline evaluation has not been established. We retrospectively studied 176 HMA-treated patients who underwent alloHSCT, applying the Molecular International Prognostic Scoring System (IPSS-M) at both diagnosis and pre-transplant. The primary endpoint was 4-year progression-free survival (PFS). Overall, dynamic assessment did not improve prognostic performance compared with baseline evaluation. For 4-year PFS, C-indices at diagnosis versus at alloHSCT were 0.6406 versus 0.6377 (p=0.82). Patients with worsening risk after HMA experienced notably inferior outcomes, while those with apparent improvement fared no better than patients with unchanged risk (4-year PFS: 50%, 50%, and 31% for improved, unchanged, and worsening risk, respectively). Apparent IPSS-M improvement before alloHSCT yielded no gains in survival and no reduction in relapse relative to unchanged risk, a pattern consistent among TP53 wild-type patients. Moreover, clearance of TP53 mutations following HMA therapy did not translate into improved post-transplant outcomes. In summary, dynamic reassessment with IPSS-M prior to alloHSCT offers no prognostic advantage over baseline evaluation at diagnosis in HMA-treated MDS patients. Accordingly, risk reduction should not be regarded as a therapeutic goal or trial endpoint, whereas risk progression constitutes an adverse marker that may inform incorporation of post-transplant maintenance strategies or intensified conditioning regimens to improve survival.

#StemCellEvidence link to:

Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation
by Aguirre et al.
www.stemcellevidence.com/alerts/artic...
#MedSky

Image showing a PICO summary for: Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation by Aguirre et al. featured in the Stem Cell Evidence Alert - March 2026

From the #StemCellEvidence Alert:

Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation
by Aguirre et al.
🔗Link in the comments.

Image showing visual abstract for: Clinical and economic outcomes of therapeutic plasma exchange and intravenous immunoglobulin for treating adults with autoimmune neurological disorders: a systematic review and meta analysis, by Kimber et al.

New systematic review by the SRI:
Clinical and economic outcomes of therapeutic #plasmaexchange and intravenous #immunoglobulin for treating adults with autoimmune neurological disorders: a #systematicreview and #metaanalysis by Kimber et al. (2026).

Link in the comments.

Image showing visual abstract for: Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders, by Champaneria et al.

Our latest Cochrane #systematicreview update on: #Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with #haematologicaldisorders by Champaneria et al. (2026) is out

This was published in 2013 and updated in 2016

Link in replies
#tranexamicacid #epsilonaminocaproicacid

Comparable outcomes of HSCT up-front and after failure of IST in pediatric aplastic anemia in recent years We investigated the outcomes of 179 pediatric patients with severe aplastic anemia (SAA) who received up-front hematopoietic stem cell transplantation (HSCT; n = 87) or received HSCT after failure of immunosuppressive therapy (IST; n = 92). With a median follow-up of 4.0 years (range, 0.2-10.7) after HSCT, 161 patients were alive at last follow-up. The cumulative incidence of graft failure, grade 2 to 4 acute and chronic graft-versus-host disease (GVHD) was 10%, 18%, and 8%, respectively. Five-year overall survival (OS) and GVHD-free, relapse/rejection-free survival (GRFS) were 89% and 79%, respectively. Patients who received up-front HSCT from a matched sibling donor (MSD) or ≥9/10 HLA-matched unrelated donor (MUD) both achieved an OS of 95%. OS was superior in patients who received up-front HSCT than those who received HSCT after failure of IST (up-front, 95% [95% CI, 89-100] vs after IST failure, 83% [95% CI,75-91]; P < .01). However, OS in the HSCT group after IST failure improved over time, resulting in comparable OS between up-front HSCT and HSCT after IST failure from 2015 (97% vs 89%; P = .09). Moreover, there was no difference in GRFS of MUD-HSCT comparing patients who received a transplant up front or after IST failure (up-front, 77% vs after IST failure, 76%; P value not significant). Our data highlight the good transplant outcomes of a consecutive pediatric SAA cohort. Although up-front HSCT from a readily available MUD is a viable option if an MSD is not available, HSCT after IST failure from a well-matched unrelated donor also yields favorable outcomes.

#StemCellEvidence link 🔗to:

Comparable outcomes of HSCT up-front and after failure of IST in pediatric aplastic anemia in recent years
by Andresen et al.
www.stemcellevidence.com/alerts/artic...

Image showing a PICO summary for: Comparable outcomes of HSCT up-front and after failure of IST in pediatric aplastic anemia in recent years by Andresen et al. featured in the Stem Cell Evidence Alert - March 2026

From the #StemCellEvidence Alert:

Comparable outcomes of HSCT up-front and after failure of IST in pediatric aplastic anemia in recent years
by Andresen et al.

🔗Link in the comments

HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study BACKGROUND: Frailty assessment has emerged as a key component of pre-transplant evaluation. We aimed to validate, across international cohorts, the Hematopoietic Cell Transplantation Frailty Scale (HC...

🔗#StemCellEvidence link to:
www.stemcellevidence.com/alerts/artic...

Image showing a PICO summary for: HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study by Salas et al. featured in the Stem Cell Evidence Alert - March 2026

New from the #StemCellEvidence Alert:

HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study
by Salas et al.
🔗Link in the comments.